WO2014186982A1 - 三七素在制备治疗血小板减少症的药物的应用 - Google Patents
三七素在制备治疗血小板减少症的药物的应用 Download PDFInfo
- Publication number
- WO2014186982A1 WO2014186982A1 PCT/CN2013/076216 CN2013076216W WO2014186982A1 WO 2014186982 A1 WO2014186982 A1 WO 2014186982A1 CN 2013076216 W CN2013076216 W CN 2013076216W WO 2014186982 A1 WO2014186982 A1 WO 2014186982A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- injection
- group
- preparation
- thrombocytopenia
- notoginseng
- Prior art date
Links
- 206010043554 thrombocytopenia Diseases 0.000 title claims abstract description 37
- 239000003814 drug Substances 0.000 title claims abstract description 35
- 229940079593 drug Drugs 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 title abstract description 16
- 239000007924 injection Substances 0.000 claims abstract description 45
- 238000002347 injection Methods 0.000 claims abstract description 45
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims abstract description 7
- 241000180649 Panax notoginseng Species 0.000 claims description 27
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 16
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 206010000830 Acute leukaemia Diseases 0.000 claims description 2
- 206010002065 Anaemia megaloblastic Diseases 0.000 claims description 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 2
- 208000000682 Megaloblastic Anemia Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000037386 Typhoid Diseases 0.000 claims description 2
- 206010047505 Visceral leishmaniasis Diseases 0.000 claims description 2
- 201000004108 hypersplenism Diseases 0.000 claims description 2
- 206010025482 malaise Diseases 0.000 claims description 2
- 231100001016 megaloblastic anemia Toxicity 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 239000006191 orally-disintegrating tablet Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 239000007939 sustained release tablet Substances 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 201000008297 typhoid fever Diseases 0.000 claims description 2
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 239000007919 dispersible tablet Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 239000002671 adjuvant Substances 0.000 abstract description 5
- 229940044683 chemotherapy drug Drugs 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 229960004562 carboplatin Drugs 0.000 description 25
- 190000008236 carboplatin Chemical compound 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 208000032843 Hemorrhage Diseases 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 15
- 230000000740 bleeding effect Effects 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 102000003815 Interleukin-11 Human genes 0.000 description 11
- 108090000177 Interleukin-11 Proteins 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- 229940074383 interleukin-11 Drugs 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- 230000006378 damage Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 206010037549 Purpura Diseases 0.000 description 5
- 241001672981 Purpura Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- MOVRKLZUVNCBIP-RFZYENFJSA-N cortancyl Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O MOVRKLZUVNCBIP-RFZYENFJSA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229910052697 platinum Inorganic materials 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 239000008678 sanqi Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 241000208340 Araliaceae Species 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 206010061298 Mucosal haemorrhage Diseases 0.000 description 4
- 230000002489 hematologic effect Effects 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 230000002439 hemostatic effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 206010014080 Ecchymosis Diseases 0.000 description 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- UAOBSVDFJSNTLJ-UHFFFAOYSA-N 4-ethenyl-4,7,7-trimethyl-5-prop-1-en-2-ylbicyclo[3.2.0]heptane Chemical compound C1CC(C=C)(C)C2(C(=C)C)C1C(C)(C)C2 UAOBSVDFJSNTLJ-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 229930189092 Notoginsenoside Natural products 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- -1 diethylstilbestrol Chemical compound 0.000 description 2
- 210000004013 groin Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 238000011519 second-line treatment Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NEEQFPMRODQIKX-UWTATZPHSA-N (2r)-2-amino-3-(oxaloamino)propanoic acid Chemical compound OC(=O)[C@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-UWTATZPHSA-N 0.000 description 1
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000307697 Agrimonia eupatoria Species 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 208000035049 Blood-Borne Infections Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010072043 Central nervous system haemorrhage Diseases 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001010568 Homo sapiens Interleukin-11 Proteins 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 240000005783 Lathyrus sativus Species 0.000 description 1
- 235000010671 Lathyrus sativus Nutrition 0.000 description 1
- 241000830535 Ligustrum lucidum Species 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 241000913745 Spatholobus Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 208000003441 Transfusion reaction Diseases 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 108010052008 colla corii asini Proteins 0.000 description 1
- 235000000125 common agrimony Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000000816 effect on animals Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 102000049885 human IL11 Human genes 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 210000003111 iliac vein Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 125000002324 prednisone group Chemical group 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000003582 thrombocytopenic effect Effects 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000007371 visceral function Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention belongs to the technical field of medicines and relates to the use of a medicament for treating thrombocytopenia, in particular to a medicament for preparing a medicament for treating thrombocytopenia.
- Platelets are the smallest blood cells. Their main function is coagulation and hemostasis. When the human body is bleeding, the platelets will rush into the wound in a few seconds. They first release the vasoconstrictor and make the damaged blood vessels different degrees. The contraction, followed by adhesion of platelets and other blood clotting substances in the blood to the damaged vessel wall, forms a blood clot that blocks the damaged wound and blood vessels.
- the number of platelets in healthy people is 100 X 10 9 /L ⁇ 300 X 10 9 /L. Its life span averages 8 to 12 days, and platelet counts are below the lower limit of reference for a variety of reasons, which is thrombocytopenia.
- Thrombocytopenia can cause the following hazards: 1. May cause mucosal bleeding (nasal mucosal hemorrhage, oral mucosal hemorrhage, gastrointestinal mucosal hemorrhage, genitourinary tract bleeding, vaginal bleeding, etc.); 2. Major bleeding after surgery; 3. Multiple ecchymosis , purpura is most often found in the legs; 4. causing massive bleeding in the gastrointestinal tract and central nervous system bleeding can be life-threatening.
- thrombocytopenia There are many causes of thrombocytopenia, such as decreased platelet production, excessive platelet destruction, and excessive platelet retention in the spleen.
- Decreased platelet production Damage to hematopoietic stem cells due to certain factors such as drugs, malignant tumors, infections, ionizing radiation, etc. or affecting their proliferation in bone marrow cells.
- Excessive platelet destruction Common idiopathic thrombocytopenic purpura and wasting thrombocytopenia, such as diffuse intravascular coagulation and thrombotic thrombocytopenic purpura.
- Platelets are excessively retained in the spleen: common in spleen function. The above factors often exist at the same time. Clinically, except for pseudo-thrombocytopenia, there is no need for treatment. Both drug-induced thrombocytopenia and pathological thrombocytopenia require treatment.
- Drug-induced thrombocytopenia is a hemorrhagic disease caused by a decrease in platelet count in peripheral blood caused by certain drugs.
- the drug-induced platelet count is less than 100 X 10 9 /L, and severe platelets can be caused.
- anticoagulant drugs such as heparin, antitumor drugs and immunosuppressants, antibacterials such as chloramphenicol and sulfonamides, antipyretic analgesics such as aspirin and Acetaminophen, diuretics such as chlorpyridin, antiepileptic drugs such as phenytoin and carbamazepine, hypoglycemic agents such as chlorpropamide and tolbutamide, estrogens such as diethylstilbestrol, certain vaccines, Certain Chinese medicine preparations, some drop It is caused by drugs such as blood lipid drugs, cimetidine, secret agents, digitalis, and organic arsenic.
- Pathological thrombocytopenia mainly includes primary and secondary thrombocytopenic purpura, aplastic anemia, acute leukemia, megaloblastic anemia, DIC, hypersplenism, radiation sickness, kala-azar, typhoid fever, tuberculosis, bone marrow metastasis and Progressive extracorporeal circulation and the like.
- thrombocytopenic purpura is the most common.
- first-line treatment glucocorticoids, intravenous immunoglobulin and splenectomy
- second-line treatment intravenous anti-Rh (D) immunoglobulin, immunosuppressant
- first-line and second-line treatment failure can be treated by platelet transfusion, plasma exchange, protein immunoadsorption and the like.
- platelet transfusion is an effective method for the treatment of thrombocytopenia.
- interleukin _11 IL-11
- thrombopoietin TP0
- thrombocytopenia Chinese medicine also has its theory of treatment.
- thrombocytopenic purpura (1TP)
- commonly used drugs include ascending platelet capsules and weixining granules.
- chemotherapy drugs are the products of attack, which are hot and toxic, can consume gas and damage yin, damage organs, especially spleen, kidney, liver and other visceral functions, so that the source of the sky Depletion and qi and blood damage, liver and kidney loss, spleen and stomach weakness and other syndromes.
- Dencichine (also known as Neurotokin), chemical name ⁇ -N-oxalyl-L- ⁇ , ⁇ -di-alanyl-L, ⁇ -diaminopropionic acid (ODAP), is a Non-protein ammonia
- the base acid is a hemostatic active ingredient in Panax notoginseng.
- Rao et al first isolated and identified the chemical structure of Dencichine from the seeds of Lathyrus sativus, and successfully synthesized the compound in 1971. The relationship between the optical activity and central toxicity of the compound was also studied. Since then, there have been reports of various synthetic methods. At present, the research on the central toxicity of Dencichine has reached the level of cellular molecules. It is believed that the central toxicity of Dencichine is mainly because Dencichine acts as an analog of L-glutamate, polarizing the central nervous cell membrane, affecting Na + , K + , Ca 2+ plasma Caused by the activity.
- the notoginseng is prepared into an oral preparation or an injection preparation by adding a pharmaceutically acceptable conventional excipient for clinical treatment of thrombocytopenia.
- the oral preparation is a tablet, a capsule, a granule or a powder; and the injection preparation is an injection or a powder injection.
- the oral preparation is preferably a dispersion tablet, an orally disintegrating tablet or a sustained release tablet; and the injection preparation is preferably an injection solution.
- the present invention has found for the first time that notoginsenoside can be used for the treatment of thrombocytopenia.
- Laboratory pharmacodynamic tests have confirmed that Panax notoginseng can effectively inhibit the treatment of thrombocytopenia and thrombocytopenic purpura caused by chemotherapy drugs, with remarkable curative effect and little side effects.
- Test animals Wistar rats, male, weighing 180_210 g, purchased from Changchun Yisi experimental animals Technology Co., Ltd. Certificate No.: SCXK- ( ⁇ ) 2011-0004
- Trimethoate Specification: 46mk/bottle, supplied by Kunming Shenghuo Pharmaceutical Group, batch number: 20120323; Freshly prepared in normal saline, stored at 4 °C, for intraperitoneal injection.
- Recombinant human interleukin-11 for injection specifications: 2. 4*10 7 AU/3. 0mg, produced by Qilu Pharmaceutical Co., Ltd., batch number: 201202008SK, sterile lyophilized preparation, stored at 4 ° C, preparation method: fresh with physiological saline Formulated for subcutaneous injection.
- Carboplatin injection specifications: 10ml: 100mg, produced by Qilu Pharmaceutical Co., Ltd., batch number: 1040042ES, stored in the dark, freshly diluted with physiological saline before use, for intravenous injection.
- Test equipment T2000 type electronic scale, produced by American Shuangjie Brothers Co., Ltd. PE-6800VET full automatic blood cell analyzer, produced by Shenzhen Pukang Electronics Co., Ltd. FB-40 blood coagulation analyzer, produced by Shenzhen Pukang Electronics Co., Ltd. CH-20 microscope, produced by Olympus Group.
- 81 rats were randomly divided into 8 groups: blank control group, high dose group A (4 mg/kg, intraperitoneal injection, no model), model group (40 mg/kg, tail vein injection), interleukin 11 groups (260 ⁇ g/kg, subcutaneous injection), high dose B (4 mg/kg, intraperitoneal injection, modeling), high dose (4 mg/kg, intraperitoneal injection), medium dose (1 mg/kg, intraperitoneal injection), Low dose (0.25 mg/kg, intraperitoneal injection) a total of eight groups, except for the model group of 11 other groups were 10. Animals were acclimated to the 2-day environment before the experiment, and blood was taken from the tail to detect hematological parameters.
- hematological parameters were measured in the blank group, the drug group A, and the positive drug group. Thereafter, all animals (except the blank group and the reagent group A) were injected with carboplatin 40 mg/kg in a single tail vein, and then administered continuously for 15 days. The 15-day trials were discontinued in groups A and B. Blood samples were taken from the tails on the 5th, 10th, and 15th day of modeling. The second injection of carboplatin 40 mg/kg was re-modeled after the 15th day of modeling, and all the administration groups were continued to be administered as described above, once a day for 10 days. Animals were weighed before each test to detect hematological parameters.
- the blood was taken from the tail of the rats to detect hematological parameters.
- the blood was taken from the tail of the rats, and the hematology, reticulocyte and coagulation indicators were detected; The animals were weighed and sacrificed; the liver, thymus, spleen, and adrenal glands were weighed, and the organ index was calculated; and the bone marrow was taken for pathology.
- the weight gain of the blank control group was normal; After administration, the body weight increased slowly compared with the control group, and there was a significant difference.
- the interleukin 11 group was administered at 280 ⁇ g/kg, subcutaneously, and the body weight was significantly reduced. The condition was poor after 10 days of preventive administration. There was a significant difference; after the injection of carboplatin, there were dead animals, and then the dose was reduced to 260 ⁇ g/kg, and the body weight and condition of the animals gradually returned to normal. During the whole administration period, the body weight of the animals injected with carboplatin was significantly lower than that of the blank group, and there was no significant difference between the other groups and the model group.
- Interleukin 11 group (9) 4.10 ⁇ 0.30** 0.39 + 0.05** 0.14 ⁇ 0.05 0.04 + 0.01**
- Prevention of high dose B (10) 3.70 ⁇ 0.31 0.36 ⁇ 0.10 0.10 ⁇ 0.03 0.03 ⁇ 0.01
- interleukin 11 significantly increased the number of platelets in the animals, which was significantly different from the control group.
- the number of platelets was still increasing.
- the number of platelets in the model group was significantly lower than that of the control group, which was reduced to 51.4%. There was no significant difference between the groups and the model group.
- the platelet count of the model group was reduced to 19.8% compared with the control group.
- the platelet count of the interleukin 11 group was significantly higher than that of the model group, and the platelet count was inhibited.
- the number of platelets in the group A was significantly higher than that in the blank control group.
- the number of platelets in the model group was significantly lower than that in the control group, which was reduced to 21.6%%.
- the platelet count and model group of the interleukin 11 group was significantly higher, and the number of platelets in the other groups was not significantly different from that in the model group, and the animal status was poor.
- Control group high-dose model group
- interleukin group prevention of high-dose, high-dose, medium-dose, low-dose, before the start of the experiment
- Prednisone acetate tablets are produced by Tianjin Pacific Pharmaceutical Co., Ltd. (National Medicine Standard H12020809).
- the prednisone acetate tablets were ground into a powder and formulated into a suspension (0.3 g/L) with physiological saline.
- mice Healthy BALB/C mice, weighing 18-22 g, were randomly divided into 6 groups, 12 in each group, blank group, model group, prednisone acetate group, and notoginseng (low, medium and high dose) groups.
- Modeling method BALB/C mice were collected from the iliac vein, EDTA-Na 2 was anticoagulated, and platelets were separated and washed. The prepared platelet suspensions were each mixed with an equal amount of complete Freund's adjuvant and incomplete Freund's adjuvant.
- the antigen containing complete Freund's adjuvant was injected into the hind paw, back and groin of guinea pigs respectively; the antigen containing incomplete Freund's adjuvant was injected into the hind legs of guinea pigs at 2, 3, and 5 weeks.
- the palm, back and groin are subcutaneous.
- the antibody titer was tested by agar diffusion method and stored in a refrigerator at -20 ° C for use.
- mice The other five groups of mice except the normal group were injected with guinea pig anti-mouse platelet serum (APS) at a dose of 100 l/20 g body weight in the abdominal cavity on days 1, 3, 5, 7, 9, 11, and 13 of the experiment.
- APS guinea pig anti-mouse platelet serum
- mice Each group of mice was gavaged from the first day of the test.
- the low, medium and high doses of Panax notoginseng were 1.5, 3, 6 mg/kg respectively; the prednisone mice were given 5 mg/(kg * d) to the prednisone acetate suspension;
- Group mice were given an equal volume of normal saline (0.2 ml / 20 g) body weight.
- the stomach was administered once a day, and I4d was continuously administered.
- Grade I Mild bleeding at the injection site, scattered bleeding at other sites.
- Grade II Significant bleeding at the injection site, and see other areas of ecchymosis, sputum.
- Grade III Severe bleeding at the injection site, large skin ecchymosis, blemishes, blackness or ulceration.
- Body weight test The body weight of each group was measured before modeling, on the 7th day of the experiment, and on the 14th day of the experiment.
- mice The body weight changes of mice in each group before modeling, on the 7th day of experiment and on the 14th day of experiment are shown in Table 7.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020157036458A KR20160012210A (ko) | 2013-05-24 | 2013-05-24 | 혈소판 감소증의 치료를 위한 조제약에서의 덴키신 사용 |
EP13885144.9A EP3006025A4 (en) | 2013-05-24 | 2013-05-24 | USE OF DENCICHIN IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF THROMBOCYTOPENIA |
US14/893,792 US9526713B2 (en) | 2013-05-24 | 2013-05-24 | Use of dencichine in preparation of drug for treating thrombocytopenia |
PCT/CN2013/076216 WO2014186982A1 (zh) | 2013-05-24 | 2013-05-24 | 三七素在制备治疗血小板减少症的药物的应用 |
EA201592232A EA201592232A1 (ru) | 2013-05-24 | 2013-05-24 | Применение денцихина в получении лекарственного средства для лечения тромбоцитопении |
BR112015029280A BR112015029280A2 (pt) | 2013-05-24 | 2013-05-24 | dencichine para a utilização no tratamento da trombocitopenia e para a utilização na fabricação de um medicamento |
JP2016514236A JP2016518455A (ja) | 2013-05-24 | 2013-05-24 | 血小板減少症治療薬の製造におけるデンシチンの使用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2013/076216 WO2014186982A1 (zh) | 2013-05-24 | 2013-05-24 | 三七素在制备治疗血小板减少症的药物的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014186982A1 true WO2014186982A1 (zh) | 2014-11-27 |
Family
ID=51932737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2013/076216 WO2014186982A1 (zh) | 2013-05-24 | 2013-05-24 | 三七素在制备治疗血小板减少症的药物的应用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9526713B2 (zh) |
EP (1) | EP3006025A4 (zh) |
JP (1) | JP2016518455A (zh) |
KR (1) | KR20160012210A (zh) |
BR (1) | BR112015029280A2 (zh) |
EA (1) | EA201592232A1 (zh) |
WO (1) | WO2014186982A1 (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1146995A (zh) * | 1995-10-05 | 1997-04-09 | 南京康星生物医学发展公司 | 血小板生成素及其生产工艺 |
CN1292377A (zh) * | 2000-08-10 | 2001-04-25 | 昆明南国生物资源开发研究所 | 高效止血药三七素的合成制备方法 |
CN1292376A (zh) | 2000-08-10 | 2001-04-25 | 昆明南国生物资源开发研究所 | 合成制备高效止血药三七素的方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5543044A (en) * | 1978-09-23 | 1980-03-26 | Takuo Kosuge | Extraction of propionic acid derivative from panax notoginseng e.h. chen, and hemostatic agent and blood platelet increasing agent containing said derivative |
JPS57114511A (en) * | 1981-08-13 | 1982-07-16 | Takuo Kosuge | Hemostatic and platelet-increasing agent comprising propionic acid derivative |
JPH06100462A (ja) * | 1992-08-05 | 1994-04-12 | Takeda Chem Ind Ltd | 血小板増加剤 |
JP2003024076A (ja) * | 2001-07-12 | 2003-01-28 | Kirin Brewery Co Ltd | Tpo変異体タンパク質 |
TW200605906A (en) * | 2004-05-11 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Remedy for thrombopenia |
CN100579542C (zh) * | 2007-08-24 | 2010-01-13 | 济南市第三人民医院 | 一种治疗血小板减少的中草药配方 |
US8362081B2 (en) * | 2009-12-31 | 2013-01-29 | Guihua Lan | Methods for treating hemorrhagic conditions |
-
2013
- 2013-05-24 JP JP2016514236A patent/JP2016518455A/ja active Pending
- 2013-05-24 EA EA201592232A patent/EA201592232A1/ru unknown
- 2013-05-24 KR KR1020157036458A patent/KR20160012210A/ko not_active Application Discontinuation
- 2013-05-24 EP EP13885144.9A patent/EP3006025A4/en not_active Withdrawn
- 2013-05-24 WO PCT/CN2013/076216 patent/WO2014186982A1/zh active Application Filing
- 2013-05-24 BR BR112015029280A patent/BR112015029280A2/pt not_active IP Right Cessation
- 2013-05-24 US US14/893,792 patent/US9526713B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1146995A (zh) * | 1995-10-05 | 1997-04-09 | 南京康星生物医学发展公司 | 血小板生成素及其生产工艺 |
CN1292377A (zh) * | 2000-08-10 | 2001-04-25 | 昆明南国生物资源开发研究所 | 高效止血药三七素的合成制备方法 |
CN1292376A (zh) | 2000-08-10 | 2001-04-25 | 昆明南国生物资源开发研究所 | 合成制备高效止血药三七素的方法 |
Non-Patent Citations (2)
Title |
---|
See also references of EP3006025A4 * |
YUAN, YAOGUANG ET AL.: "Clinical Application of Blood Platelet", CHINESE JOURNAL OF BLOOD TRANSFUSION, vol. 17, no. 2, April 2004 (2004-04-01), pages 106 - 107, XP008181003 * |
Also Published As
Publication number | Publication date |
---|---|
EP3006025A1 (en) | 2016-04-13 |
JP2016518455A (ja) | 2016-06-23 |
EA201592232A1 (ru) | 2016-04-29 |
KR20160012210A (ko) | 2016-02-02 |
EP3006025A4 (en) | 2016-12-28 |
BR112015029280A2 (pt) | 2017-07-25 |
US9526713B2 (en) | 2016-12-27 |
US20160089351A1 (en) | 2016-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101512495B1 (ko) | 혈구 감소 관련 질환 예방 및 치료용 약물을 제조하기 위한 악티게닌의 용도 | |
CN102940779B (zh) | 一种治疗慢性溃疡性结肠炎的药物组合物及其制备方法 | |
CN111110824B (zh) | 扶正救肺药物组合物及其应用 | |
CN103989668A (zh) | 连翘苷元在制备预防或治疗肝损伤或肝衰竭药物中的应用 | |
CN101259139A (zh) | 一种用于消炎镇痛的药用组合物 | |
CN114869928B (zh) | 用于治疗脑血管疾病的中药组合物及其用途 | |
CN105982887A (zh) | 牛蒡子苷元在制备治疗高粘滞血症药物中的用途 | |
WO2014186982A1 (zh) | 三七素在制备治疗血小板减少症的药物的应用 | |
CN102552440B (zh) | 一种平喘消炎药物及其制备方法和用途 | |
CN115154461B (zh) | 白术内酯i在制备治疗干燥综合征药物中的应用 | |
JP2016537428A (ja) | エフェドラ・アラタ抽出物及びその使用方法 | |
CN117562895B (zh) | 白术内酯ⅰ在制备用于治疗过敏性紫癜的药物中的应用 | |
CN107213323B (zh) | 一种滋阴化痰、散结解毒的中药复方制剂及其用途 | |
CN111374978B (zh) | 沙利度胺在制备改善地中海贫血患者肝功能损害的药物组合物中的应用 | |
JPS59225122A (ja) | 悪液質治療改善剤 | |
Horoshko | Influence of nano-drugs on lipid and protein peroxidation processes in experimental acute renal failure | |
CN113876764A (zh) | 包含维甲酸的药物组合物在制备治疗特发性血小板减少性紫癜的药物中的用途 | |
KR20100112597A (ko) | 동충하초 균사체 추출물을 유효성분으로 함유하는 면역 억제용 조성물 | |
CN104473957B (zh) | 一种用于降脂的中药单体组合物及其制剂 | |
WO2015100579A1 (zh) | 一种用于治疗艾滋病的药物组合物及其制备方法 | |
CN105687181B (zh) | 连翘苷元在制备治疗乙型病毒性肝炎药物中的用途 | |
Semwal | Development and challenges of herbal injectables–a possible emerging area of drug delivery | |
CN104474227A (zh) | 一种治疗肝炎合并再生障碍性贫血的中药组合物 | |
CN102872140B (zh) | Houttuynoid C在制备治疗急性肾衰药物中的应用 | |
CN102861095B (zh) | Houttuynoid E在制备治疗急性肾衰药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13885144 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201507388 Country of ref document: ID |
|
ENP | Entry into the national phase |
Ref document number: 2016514236 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14893792 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013885144 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015029280 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201592232 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 20157036458 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112015029280 Country of ref document: BR Kind code of ref document: A2 Effective date: 20151123 |